CVRx Inc (CVRX)vsNovartis AG ADR (NVS)
CVRX
CVRx Inc
$2.88
+0.70%
HEALTHCARE · Cap: $76.73M
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 92554% more annual revenue ($56.69B vs $61.19M). NVS leads profitability with a 22.5% profit margin vs -84.9%. NVS earns a higher WallStSmart Score of 51/100 (C-).
CVRX
Avoid31
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+70.8%
Fair Value
$20.80
Current Price
$2.88
$17.92 discount
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
15.6% revenue growth
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -180.9% — below average capital efficiency
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : CVRX
The strongest argument for CVRX centers on Revenue Growth. Revenue growth of 15.6% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : CVRX
The primary concerns for CVRX are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 2.98 is elevated, increasing financial risk.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
CVRX profiles as a growth stock while NVS is a value play — different risk/reward profiles.
CVRX carries more volatility with a beta of 0.76 — expect wider price swings.
CVRX is growing revenue faster at 15.6% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 31/100), backed by strong 22.5% margins. CVRX offers better value entry with a 70.8% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CVRx Inc
HEALTHCARE · MEDICAL DEVICES · USA
CVRx, Inc. develops implantable technology for the treatment of patients with high blood pressure / hypertension and heart failure.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?